Moderna Inc.

60.59+0.7000+1.17%Vol 13.41M1Y Perf 209.24%
Jun 4th, 2020 16:00 DELAYED
BID60.51 ASK60.59
Open61.61 Previous Close59.89
Pre-Market- After-Market-
 - -%  - -%
Target Price
80.89 
Analyst Rating
Strong Buy 1.39
Potential %
33.50 
Finscreener Ranking
★★★+     51.95
Insiders Trans % 3/6/12 mo.
-100/-99/-99 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-100/-98/-98 
Growth Ranking
★★+     48.07
Insiders Shares Cnt. % 3/6/12 mo.
-100/-96/-96 
Income Ranking
 —    -
Market Cap22.49B 
Earnings Rating
Strong Buy
Price Range Ratio 52W %
65.00 
Earnings Date
7th May 2020

Today's Price Range

58.5261.93

52W Range

11.5487.00

Summary:

Buy

Technical Indicators: Buy
Moving Averages: Strong Buy
Performance
1 Week
-1.48%
1 Month
22.80%
3 Months
116.32%
6 Months
193.56%
1 Year
209.24%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
MRNA60.590.70001.17
AAPL322.32-2.8000-0.86
GOOG1 412.18-24.2000-1.68
MSFT182.92-2.4400-1.32
XOM49.10-0.1400-0.28
WFC30.361.53005.31
JNJ146.73-1.9200-1.29
FB226.29-3.8700-1.68
GE7.740.38005.16
JPM106.442.17002.08
Earnings HistoryEstimateReportedSurprise %
Q01 2020-0.37-0.355.41
Q04 2019-0.43-0.3713.95
Q03 2019-0.43-0.3713.95
Q02 2019-0.42-0.412.38
Q01 2019-0.35-0.40-14.29
----
----
----
Earnings Per EndEstimateRevision %Trend
6/2020 QR-0.40-8.11Negative
9/2020 QR-0.44-15.79Negative
12/2020 FY-1.511.31Positive
12/2021 FY-0.4272.90Positive
Next Report Date-
Estimated EPS Next Report-0.37
Estimates Count5
EPS Growth Next 5 Years %33.60
Volume Overview
Volume13.41M
Shares Outstanding371.22M
Trades Count122.58K
Dollar Volume787.60M
Avg. Volume17.15M
Avg. Weekly Volume22.80M
Avg. Monthly Volume33.84M
Avg. Quarterly Volume21.45M

Moderna Inc. (NASDAQ: MRNA) stock closed at 60.59 per share at the end of the most recent trading day (a 1.17% change compared to the prior day closing price) with a volume of 13.50M shares and market capitalization of 22.49B. Is a component of Russell 1000 indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 760 people. Moderna Inc. CEO is Stephane Bancel.

The one-year performance of Moderna Inc. stock is 209.24%, while year-to-date (YTD) performance is 209.76%. MRNA stock has a five-year performance of %. Its 52-week range is between 11.54 and 87, which gives MRNA stock a 52-week price range ratio of 65.00%

Moderna Inc. currently has a PE ratio of -, a price-to-book (PB) ratio of 13.91, a price-to-sale (PS) ratio of 439.06, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -26.11%, a ROC of -32.70% and a ROE of -32.76%. The company’s profit margin is -%, its EBITDA margin is -890.90%, and its revenue ttm is $52.57 Million , which makes it $0.14 revenue per share.

Of the last four earnings reports from Moderna Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-0.37 for the next earnings report. Moderna Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Moderna Inc. is Strong Buy (1.39), with a target price of $80.89, which is +33.50% compared to the current price. The earnings rating for Moderna Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Moderna Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Moderna Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 35.98, ATR14 : 6.41, CCI20 : -35.84, Chaikin Money Flow : 0.09, MACD : 2.71, Money Flow Index : 47.47, ROC : -15.46, RSI : 52.79, STOCH (14,3) : 35.38, STOCH RSI : 0.82, UO : 55.86, Williams %R : -64.62), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Moderna Inc. in the last 12-months were: Elizabeth G. Nabel (Sold 30 000 shares of value $1 980 000 ), Jennifer L. Lee (Sold 361 shares of value $9 866 ), Juan Andres (Option Excercise at a value of $2 840 156), Juan Andres (Sold 232 609 shares of value $12 156 586 ), Lorence H. Kim (Option Excercise at a value of $18 500 536), Lorence H. Kim (Sold 1 121 532 shares of value $57 488 366 ), Lori M. Henderson (Option Excercise at a value of $950 400), Lori M. Henderson (Sold 64 000 shares of value $4 480 000 ), Paul Sagan (Buy at a value of $999 989), Peter Barton Hutt (Option Excercise at a value of $12 000), Peter Barton Hutt (Sold 300 000 shares of value $5 799 000 ), Stephane Bancel (Sold 485 135 shares of value $14 886 829 ), Stephen Hoge (Sold 99 990 shares of value $3 352 931 ), Tal Zaks (Option Excercise at a value of $4 665 927), Tal Zaks (Sold 579 902 shares of value $31 355 637 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
6 (66.67 %)
5 (62.50 %)
6 (75.00 %)
Moderate Buy
2 (22.22 %)
2 (25.00 %)
2 (25.00 %)
Hold
1 (11.11 %)
1 (12.50 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.39
Strong Buy
1.44
Strong Buy
1.19

Moderna Inc.

Moderna Inc is engaged in creating transformative medicines based on messenger RNA, or mRNA. Its therapeutic and vaccine development programs span infectious diseases, oncology, cardiovascular diseases, and rare genetic diseases. The company's approach is to use mRNA medicines to instruct a patient's own cells to produce proteins that could prevent, treat, or cure disease.

CEO: Stephane Bancel

Teplephone: +1 617 714-6500

Address: 200 Technology Square, Cambridge 02139, MA, USA

Number of employees: 760

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

48%52%

Bearish Bullish

47%53%

Bearish Bullish

46%54%

News

Stocktwits